[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619673":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":30,"locations":39,"responsibleParty":77,"collaborators":79,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":25,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":25,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":25,"overallStatus":42,"whyStopped":25,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Ikaria Bioscience Pty Ltd","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"RN5681","EXPERIMENTAL","Drug: RN5681 Investigational product subcutaneous injections",[13],"Drug: RN5681",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Drug: Placebo control 0.9% normal saline subcutaneous injection",[19],"Drug: Placebo control",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Investigational Product",[9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Placebo control","0.9% normal saline SC injection",[15],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Dan Xiang","CONTACT","+86 18516063568","dan.xiang@ronatherapeutics.com",{"name":37,"role":33,"phone":38,"phoneExt":25,"email":38},"Jie Zeng","jie.zeng@ronatherapeutics.com",[40,61],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Q-Pharm Pty Ltd.","RECRUITING","Brisbane","Queensland","4006","Australia","AU",{"type":49,"coordinates":50},"Point",[51,52],153.02809,-27.46794,{"lat":52,"lon":51},[55,59],{"name":56,"role":33,"phone":57,"phoneExt":25,"email":58},"Emma Trowbridge","(07) 3707 2720","e.trowbridge@nucleusnetwork.com.au",{"name":56,"role":60,"phone":25,"phoneExt":25,"email":25},"PRINCIPAL_INVESTIGATOR",{"facility":62,"status":42,"city":63,"state":64,"zip":65,"country":46,"countryCode":47,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Nucleus Network Pty Ltd.","Melbourne","Victoria","3004",{"type":49,"coordinates":67},[68,69],144.96332,-37.814,{"lat":69,"lon":68},[72,76],{"name":73,"role":33,"phone":74,"phoneExt":25,"email":75},"Philip Ryan, MD","(03) 8593 9801","p.ryan@nucleusnetwork.com.au",{"name":73,"role":60,"phone":25,"phoneExt":25,"email":25},{"type":78,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[80],{"name":81,"class":6},"Shanghai Rona Therapeutics Co., Ltd.","100619673","phase-1-phase-1a-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-rn5681-in-healthy-volunteers-100619673",false,"NCT07347678","Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RN5681 in Healthy Volunteers","A Phase 1a, Randomized, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RN5681 in Healthy Volunteers","Inclusion Criteria:\n\n* Body mass index (BMI) 18 to 35 kg\u002Fm2\n* Fasting LDL-C ≥70 mg\u002FdL (1.81 mmol\u002FL) (all SAD cohorts); fasting LDL-C ≥100 mg\u002FdL (2.59 mmol\u002FL) (POC cohort only)\n* Lp(a) at Screening: SAD cohort: ≥25 nmol\u002FL POC cohort: ≥100 nmol\u002FL\n* Fasting triglycerides \\\u003C400 mg\u002FdL (4.51 mmol\u002FL) at Screening\n* No clinically significant abnormalities of hepatic or renal function\n\nExclusion Criteria:\n\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>1.5× the upper limit of normal at screening\n* Hemoglobin A1c (HbA1c) ≥6.5% at screening\n* Current regular smoker (defined as \\>2 cigarettes\u002Fday or \\>10 cigarettes\u002Fweek) within 3 months prior to screening\n* Use of any siRNA, antisense oligonucleotide (ASO), cell and gene therapy, or clustered regularly interspaced short palindromic repeats (CRISPR) agent in the prior 12 months\n* Received any prescription lipid-lowering medication, including but not limited to statins, ezetimibe, and PCSK9 inhibitors to alter serum lipids within 30 days before screening",true,"ALL","18 Years","65 Years",{"count":94,"type":95},60,"ESTIMATED","INTERVENTIONAL",[98],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of single doses of RN5681 in Adult healthy subjects",[101],"High Cholesterol","2026-03-30",{"date":104,"type":105},"2026-04-03","ACTUAL",{"date":107,"type":105},"2026-03-12",{"date":109,"type":95},"2027-07",{"name":5,"class":6},2]